Clinical Trials
Astrazeneca: Selumetinib granted orphan drug designation in Japan for neurofibromatosis type 1
AstraZeneca announced that selumetinib has been granted orphan drug designation (ODD) in Japan for the treatment of neurofibromatosis type 1 (NF1), a rare and...
News
Stevanato Group: planned investments under the 2020-2023 industrial plan – about 400 million euros to finance the company development
Italy-based Stevanato Group, a leading producer of pharmaceutical glass containers and integrated provider of drug delivery systems, continued its growth in 2019, recording a...
News
Takeda forms $900m research alliance with Carmine Therapeutics
Japanese pharmaceutical giant Takeda Pharmaceutical has entered into a research collaboration agreement with US-based Carmine Therapeutics for the discovery, development and commercialisation of rare...
News
CSL Behring to Acquire uniQure’s Late-Stage Hemophilia B Gene Therapy
Global biotherapeutics leader CSL Behring announced that it has agreed to acquire exclusive global license rights to commercialize an adeno-associated virus (AAV) gene therapy...
Press Releases
PCI Pharma Services Announces Completion of Biotech Center of Excellence in Philadelphia and Expansions to Biotech Capabilities in Europe
PCI Pharma Services (PCI), a leading pharmaceutical and biopharmaceutical global outsourcing solutions provider, announced the completion of the expansion of its new Biotech Center...
Clinical Trials
LabCorp Introduces Xcellerate COVID-19 Clinical Study Solution
LabCorp, a leading global life sciences company that is deeply integrated in guiding patient care, announced that Covance, its drug development business, has deployed...
Press Releases
Tiziana announces agreement with STC Biologics for manufacturing of TZLS-501
Tiziana Life Sciences plc, a clinical stage biotechnology company developing targeted drugs for cancer, inflammatory diseases and COVID-19, announces the execution of an agreement...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read